A Polygenic Risk Score Assessment Reveals More Screening Participants with Clinically Significant Prostate Cancer Than Those Who Would Be Identified with PSA or MRI By Ogkologos - April 30, 2025 89 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the BARCODE1 study Source RELATED ARTICLESMORE FROM AUTHOR Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer MOST POPULAR Breast Cancer Survivor Driven from Her Home by Noxious Gases from... June 11, 2021 New Research in Treating Lymphoma and Improving Equity in Cancer Clinical... February 3, 2022 Research with integrity – the importance of communication November 14, 2022 Why I Work to Bridge the Gap Between People With Cancer... May 27, 2021 Load more HOT NEWS Woman Suffers Seizure And Dies After Making Fatal Error With Her... Antioxidant Use Before And During Chemo Increases Risk Of Relapse, Death... EMA Recommends Extension of Therapeutic Indications for Selpercatinib FDA Approves Daratumumab and Hyaluronidase-fihj With Pomalidomide and Dexamethasone for Multiple...
